Clinical trial
AE-941 in Treating Patients With Metastatic Kidney Cancer
NCT00005995 · AEterna Zentaris, Industry · Completed
Key facts
| NCT number | NCT00005995 |
|---|---|
| Title | AE-941 in Treating Patients With Metastatic Kidney Cancer |
| Official title | AE-941 (NEOVASTAT) Versus Placebo in Metastatic Renal Cell Carcinoma Patients Who Are Refractory to Immunotherapy |
| Lead sponsor | AEterna Zentaris, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Drug |
| Interventions | shark cartilage extract AE-941 |
| Start date | Oct 1, 2000 |
| Primary completion | Mar 1, 2007 |
| First posted | Feb 12, 2004 |
| Last update posted | Mar 5, 2013 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: